Cat. No. 0680
Chemical Name: N-[2-(5-Methoxy-2-phenylindol-3-yl)
Biological ActivityHighly potent melatonin agonist; displays higher affinity and greater potency than melatonin itself. The EC50 values for G protein activation in MT1 and MT2-transfected cells are 65 and 58 pM respectively.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Nonno et al (1999) Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists. Br.J.Pharmacol. 127 1288. PMID: 10455277.
Nonno et al (1998) Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells. Br.J.Pharmacol. 124 485. PMID: 9647472.
Spadoni et al (1993) 2-Substituted 5-methoxy-N-acetyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity. J.Med.Chem. 36 4069. PMID: 8258829.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses 2-Phenylmelatonin from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: 2-Phenylmelatonin, supplier, Potent, melatonin, agonists, MT, Receptors, Tocris Bioscience, Melatonin Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands